TMS Co., Ltd. (4891.T)
JPY 178.0
(0.56%)
JPY 178.0
(0.56%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -943.25 Million JPY | -81.34% |
| 2022 | -520.14 Million JPY | -145.8% |
| 2021 | 1.13 Billion JPY | 257.47% |
| 2020 | -721.15 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -223.25 Million JPY | 40.74% |
| 2024 Q2 | -228.99 Million JPY | -2.57% |
| 2023 Q1 | -151.76 Million JPY | -41.13% |
| 2023 Q4 | -376.74 Million JPY | -70.17% |
| 2023 FY | -943.25 Million JPY | -81.34% |
| 2023 Q2 | -193.34 Million JPY | -27.4% |
| 2023 Q3 | -221.39 Million JPY | -14.51% |
| 2022 Q2 | -133.5 Million JPY | 0.0% |
| 2022 FY | -520.14 Million JPY | -145.8% |
| 2022 Q4 | -107.53 Million JPY | 25.84% |
| 2022 Q3 | -145 Million JPY | -8.61% |
| 2021 FY | 1.13 Billion JPY | 257.47% |
| 2020 FY | -721.15 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 258.046% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -89.84% |
| GNI Group Ltd. | 13.1 Billion JPY | 107.196% |
| Linical Co., Ltd. | 725.72 Million JPY | 229.974% |
| Trans Genic Inc. | 89.43 Million JPY | 1154.668% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 33.851% |
| Soiken Holdings Inc. | -610 Million JPY | -54.63% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | -22.066% |
| AnGes, Inc. | -11.96 Billion JPY | 92.118% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 15.841% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 90.098% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 1004.374% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | -9.12% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 15.553% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 25.257% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | -18.12% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -179.594% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 21.733% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 29.376% |
| PeptiDream Inc. | 6.77 Billion JPY | 113.927% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 51.126% |
| Ribomic Inc. | -1.11 Billion JPY | 15.494% |
| SanBio Company Limited | -4.53 Billion JPY | 79.219% |
| Healios K.K. | -3.37 Billion JPY | 72.085% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 18.339% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 32.311% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 32.769% |
| StemRIM | -2.07 Billion JPY | 54.564% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 177.221% |
| FunPep Company Limited | -994 Million JPY | 5.105% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -6.131% |
| Stella Pharma Corporation | -760.3 Million JPY | -24.063% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -21.649% |
| Cuorips Inc. | -588.48 Million JPY | -60.284% |
| K Pharma,Inc. | 366.05 Million JPY | 357.679% |
| Takara Bio Inc. | 3 Billion JPY | 131.41% |
| ReproCELL Incorporated | -409.29 Million JPY | -130.459% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 8626.195% |
| StemCell Institute Inc. | 413.75 Million JPY | 327.972% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 752.739% |
| CellSeed Inc. | -697.77 Million JPY | -35.18% |